Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (NASDAQ: IRTC), Eyenovia (NASDAQ: EYEN) and Inhibikase Therapeutics (NASDAQ: IKT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Irhythm Technologies (IRTCResearch Report), Eyenovia (EYENResearch Report) and Inhibikase Therapeutics (IKTResearch Report).

Irhythm Technologies (IRTC)

In a report released today, Eugene Mannheimer from Colliers Securities maintained a Hold rating on Irhythm Technologies. The company’s shares closed last Wednesday at $53.90, close to its 52-week low of $53.56.

According to TipRanks.com, Mannheimer is a 4-star analyst with an average return of 18.5% and a 56.3% success rate. Mannheimer covers the Technology sector, focusing on stocks such as Computer Programs and Systems, NextGen Healthcare, and Castlight Health.

The word on The Street in general, suggests a Hold analyst consensus rating for Irhythm Technologies with a $81.00 average price target, which is a 37.3% upside from current levels. In a report issued on July 13, BTIG also downgraded the stock to Hold.

See today’s analyst top recommended stocks >>

Eyenovia (EYEN)

Northland Securities analyst Tim Chiang reiterated a Buy rating on Eyenovia yesterday and set a price target of $12.00. The company’s shares closed last Wednesday at $4.71.

According to TipRanks.com, Chiang is a 1-star analyst with an average return of -1.8% and a 50.0% success rate. Chiang covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Protagonist Therapeutics, and Verrica Pharmaceuticals.

Currently, the analyst consensus on Eyenovia is a Moderate Buy with an average price target of $12.00.

Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics received a Buy rating and a $12.00 price target from JonesTrading analyst Soumit Roy today. The company’s shares closed last Wednesday at $2.44, close to its 52-week low of $2.38.

According to TipRanks.com, Roy is a 5-star analyst with an average return of 35.2% and a 41.5% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Monopar Therapeutics Inc.

Currently, the analyst consensus on Inhibikase Therapeutics is a Moderate Buy with an average price target of $12.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.